De novo (pretreatment) epidermal growth factor receptor T790M mutation in non-small-cell lung cancer (NSCLC) is rare when detected by standard genotyping methods. We present a case of concurrent de novo T790M and L858R mutations detected by direct sequencing in treatment-naïve metastatic NSCLC. This case is worthy of mention as the presence of this mutation has a bearing on the choice of treatment. This article aims to evaluate the clinical outcome for metastatic NSCLC with de novo T790M mutation and formulate an optimum treatment plan in this clinical scenario. The novel targeted therapy agents have also been reviewed.
INTRODUCTION
Epidermal growth factor receptor (EGFR) T790M is the most common cause of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). [1] On the other hand, de novo (pretreatment) EGFR T790M mutation is rare when detected by standard genotyping methods. [2] It coexists with an activating EGFR mutation.
Here, we present a case of concurrent de novo T790M and L858R mutations in treatment-naïve metastatic non-small-cell lung cancer (NSCLC). This case is worthy of mention as the presence of this mutation has a bearing on the choice of treatment. Challenges, in this case, were to evaluate the clinical outcome for metastatic NSCLC with pretreatment T790M mutation and formulate the optimum treatment plan in this scenario.
CASE REPORT
A 40-year-old Indian female, never-smoker, presented with low back ache and pain in the right side of the chest for 3 months. She had no comorbidities. On examination, she was found to have performance status score of 1 as per Eastern Cooperative Oncology Group. Examination of the respiratory system was within normal limits. There was tenderness in the thoracolumbar spine. She had no neurologic deficits. Rest of the systemic examination was normal.
Chest radiograph showed a coin lesion in the right mid zone. Bronchoscopy was normal. Positron emission tomography/computerized tomography (PET/CT) scanning [ Figure 1a and b] showed a mass in the right upper lobe with a standardized uptake value (SUV) of 10.1. There were multiple bilateral lung nodules and mediastinal and hilar
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Concurrent T790M and L858R mutations in treatment-naïve metastatic non-small-cell lung cancer: A therapeutic challengeCurrent treatment strategies and promising therapies of the future in a nutshell This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. lymph nodes with SUVs of 5.4 and 7.6, respectively. There were metabolically active lesions in the ribs, vertebrae, manubrium and body of sternum, acetabulum of the left hip joint, and greater trochanter of the right femur. CT-guided biopsy of the lesion in the right upper lobe was suggestive of adenocarcinoma. Immunohistochemistry was positive for Napsin A, cytokeratin 7 (CK 7), and thyroid transcription factor-1. CK 20 was negative. EGFR testing by direct sequencing [ Figure 2 ] revealed two separate EGFR mutations, namely, L858R mutation in exon 21 and a de novo T790M mutation in exon 20. Anaplastic lymphoma kinase gene rearrangement was absent.
She was diagnosed with adenocarcinoma lung, Stage IV, with concurrent pretreatment T790M, and L858R mutations.
We explored the different treatment options
We reviewed the literature regarding the use of erlotinib, a first generation TKI. As per the EURopean TArceva versus Chemotherapy (EURTAC) trial and a study by Su et al., those who had a de novo T790M mutation had a shorter progression-free survival (PFS) when treated with standard TKIs (erlotinib) compared with platinum-based chemotherapy [ Table 1 ]. [3, 4] We then explored the role of afatinib, a second-generation irreversible TKI. Pooled analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung six trials has revealed that first-line afatinib showed response rates of 14.3% and duration of response of only 8 months for 14 patients with de novo T790M mutation, with or without activating mutations. On the other hand, those with activating mutations alone have shown a response rate of 70% and duration of response of 11 months with afatinib. [5] Hence, platinum doublet chemotherapy was the treatment of choice in this scenario. She was started on pemetrexed (500 mg/m 2 ) and carboplatin (area under the curve, 5) every 3 weeks along with zoledronic acid 4 mg every 4 weeks. She received palliative radiation therapy to the first lumbar vertebra (30 Gy/10 fractions). There was no improvement in the neurological deficit. She refused further treatment and opted for hospice care.
Clinical course

DISCUSSION
EGFR mutations have been identified in 15% to 20% of adenocarcinomas of the lung in non-Asians and up to 50% of Asian patients. [6] [7] [8] The incidence of EGFR mutations in the Indian population is 32%. There is a higher incidence among South Indians (47%) as compared to the North Indian population (27%). [9] Treatment-naive, advanced stage adenocarcinoma patients with sensitizing EGFR mutations, have improved response rates, PFS, and quality of life. [8, [10] [11] [12] [13] [14] [15] [16] [17] However, these patients inevitably develop progressive disease. This is due to acquired resistance; wherein there is the development of a second site mutation, T790M in up to 50% of the cases. [18] [19] [20] The EGFR mutation types have been grouped according to their response to gefitinib and erlotinib. Sensitive mutations, also called responders are exon 19 deletion and exon 21 point mutation (L858R). Possible responders are exon 21 point mutation (L861Q), point mutation at exon 18, dual mutations involving exon 19 or 21, and dual mutations with exon 20 S768I. The resistant mutations, also called nonresponders are exon 20 insertion, exon 20 point mutation (T790M), and single mutation at exon 20 S768I. [21] De novo T790M mutation coexists with an activating EGFR mutation. The incidence depends on the method used for detection of the mutation. [22, 23] When direct sequencing is used, the incidence ranges from 0.4% to 3% of all NSCLC and 1-8% of all NSCLC with an activating mutation. [2] When more sensitive assays such as mass spectrometry, mutant-enriched polymerase chain reaction (PCR), laser microdissection, and peptide nucleic acid clamping PCR or colony hybridization assays are employed, it ranges from 31% to 79% of NSCLC with an activating mutation. [4, 24, 25] It can also occur as a germline mutation which raises the possibility of genetic susceptibility and familial association. [26] [27] [28] Patients with baseline EGFR T790M mutation have a shorter median overall survival of 16 months. This is similar to that in patients with EGFR wild-type tumors and half of what is seen in patients with sensitizing EGFR-mutant tumors. [29] T790M mutation is the result of substitution of methionine for Threonine at position 790. The resultant effect of this mutation has been illustrated in Figure 6 . [18, 30] EURTAC, LUX-Lung 2, 3, and six trials have shown that this mutation confers a poorer response to standard TKI therapy and outranks the ability of the coexisting sensitizing mutation to act as an oncogenic driver. [3, 4] We also reviewed the literature with regard to the newer treatment options. CO-1686 (rociletinib) is a novel covalent inhibitor. It is an oral targeted therapy drug that irreversibly and selectively targets both the initial activating EGFR mutations and the T790M secondary acquired resistance mutation. In the Phase I study, and based on early findings from the ongoing Phase II trial, rociletinib yielded an overall response of 58% rate across all dose levels in trial participants with biopsy-confirmed EGFR T790M mutations. Furthermore, it did not cause the rash and diarrhea commonly associated with earlier generations of EGFR inhibitors. The important side effects (all grades) were nausea (25%), fatigue (21%), and impaired glucose tolerance/hyperglycemia (21%). Hyperglycemia was well managed with oral hypoglycemic agents and/or dose reduction. [31] AZD9291 is an orally bioavailable, selective, third generation TKI, effective against both sensitive and resistant (T790M) mutations. In a Phase I study, the overall response rate was 51%. Patients with EGFR T790M positive tumors had higher overall response rates compared to those with EGFR T790M negative tumors. The most common adverse events were diarrhea, rash, and nausea. [32] Dacomitinib is an oral, irreversible, small-molecule pan-HER (EGFR, HER2, and HER4) inhibitor. While preclinical studies have shown anti-tumor activity against T790M mutation-positive cell lines, [33] the clinical activity of dacomitinib in patients with EGFR T790M mutation remains to be tested in larger populations. None of the four patients with EGFR exon 20 T790M mutations responded to dacomitinib in the article by Jänne PA et al.; [34] however, one patient with a secondary exon 20 T790M mutation in the Japanese study by Takahashi et al. had sustained stable disease of 179 days with a 29% reduction in target lesion. [35] Review of literature revealed a similar case report of concurrent de novo T790M and L858R mutation in treatment naïve advanced NSCLC by Saxena et al. [36] Their patient was an 81-year-old, Chinese male, never smoker who presented with locally advanced poorly differentiated adenocarcinoma. Based on the activating mutation in exon 21, he was given erlotinib 150 mg orally daily. A PET/CT scan done 8 weeks later showed progressive disease. He had increased burden of intrapulmonary metastatic disease, worsening pleural effusion, and new lytic bone metastasis involving T5 and L1 vertebral bodies. The authors planned to discontinue erlotinib and switch over to systemic chemotherapy. However, the patient refused further treatment and opted for hospice care. This case report prompted us to opt for first-line chemotherapy for our patient. She was young, fit and had no comorbidities. Unfortunately, she experienced disease progression.
CONCLUSION
Drug therapy tailored for the individual patient in NSCLC should include a genetic assessment of EGFR mutational status. Erlotinib, gefitinib, and afatinib are currently available for patients with NSCLC, who harbor EGFR mutations. De novo T790M mutations confer a poor response to standard TKI therapy. As of today, cytotoxic chemotherapy may offer the best chance for response. Newer TKIs offer promise in this challenging clinical scenario.
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